CONTE, PIERFRANCO

CONTE, PIERFRANCO  

Mostra records
Risultati 1 - 20 di 589 (tempo di esecuzione: 0.045 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 2023 Miglietta, FDieci, M VConte, P FGuarneri, V + CANCER TREATMENT REVIEWS - -
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial 2023 Dieci, Maria VittoriaConte, PierfrancoGuarneri, Valentina + NPJ BREAST CANCER - -
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 2022 Griguolo, GaiaTosi, AnnaDieci, Maria VittoriaVentura, AnnaveraBottosso, MicheleMiglietta, FedericaFassan, MatteoConte, PierFrancoRosato, AntonioGuarneri, Valentina + NEURO-ONCOLOGY - -
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study 2022 Dieci, Maria VChiarion-Sileni, VannaLonardi, SaraDi Liso, ElisabettaMioranza, EleonoraBaldoni, AlessandraMaruzzo, MarcoCelestino, MicheleConte, PierfrancoGuarneri, Valentina + EUROPEAN JOURNAL OF CANCER - -
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer 2022 Buja, AlessandraPasello, GiuliaSchiavon, MarcoRivera, MicheleCozzolino, ClaudiaDe Polo, AnnaScioni, ManuelaBaldo, VincenzoConte, PierFranco + THORACIC CANCER - -
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 2022 Guarneri, ValentinaGriguolo, GaiaDieci, Maria VittoriaConte, Pierfranco + EBIOMEDICINE - -
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 2022 Federica MigliettaGaia GriguoloMichele BottossoTommaso GiarratanoMatteo FassanMatilde CacciatoreElisa GenovesiDebora De BartoloGrazia VernaciOttavia AmatoFrancesca PorraPierFranco ConteValentina GuarneriMaria Vittoria Dieci + NPJ BREAST CANCER - -
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 2022 Griguolo, GaiaDieci, Maria VittoriaMiglietta, FedericaGiarratano, TommasoConte, PierFrancoGuarneri, Valentina + JOURNAL OF THE NATIONAL CANCER INSTITUTE - -
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 2022 Guarneri, ValentinaDieci, Maria VittoriaGriguolo, GaiaMiglietta, FedericaBottosso, MicheleGiorgi, Carlo AlbertoConte, PierFranco + EBIOMEDICINE - -
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 2022 Bonanno, LauraDal Maso, AlessandroZulato, ElisabettaPasello, GiuliaGuarneri, ValentinaConte, PierFrancoIndraccolo, Stefano + BRITISH JOURNAL OF CANCER - -
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors 2022 Del Bianco, PaolaBoscolo Bragadin, AndreaMarra, LudovicaPasello, GiuliaFassan, MatteoCalabrese, FiorellaGuarneri, ValentinaConte, Pier FrancoIndraccolo, StefanoBonanno, Laura + BRITISH JOURNAL OF CANCER - -
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab 2022 Pasello, GiuliaLorenzi, MartinaCrivellaro, GiovannaBortolami, AlbertoBonanno, LauraGuarneri, ValentinaConte, PierFranco + THE ONCOLOGIST - -
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 2022 Dieci, Maria VittoriaGuarneri, ValentinaTosi, AnnaVernaci, Grazia MariaGriguolo, GaiaUrso, LoredanaRosato, AntonioConte, Pierfranco + CLINICAL CANCER RESEARCH - -
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 2022 Guarneri, VGriguolo, GMiglietta, FConte, P FDieci, M V + ESMO OPEN - -
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome 2022 Pavan, AlbertoFortarezza, FrancescoSchiavon, MarcoEvangelista, LauraPezzuto, FedericaLunardi, FrancescaBonanno, LauraRea, FedericoGuarneri, ValentinaConte, PierFrancoCalabrese, FiorellaPasello, Giulia + THE ONCOLOGIST - -
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F.Bonanno, L. + JOURNAL OF THORACIC ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Bonanno, L.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 2021 Bonanno, L.Dal Maso, A.Zulato, E.Fassan, M.Pasello, G.Guarneri, V.Calabrese, F.Rea, F.Indraccolo, S.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
Breast-gynaecological & immuno-oncology international cancer conference (Bgicc) consensus and recommendations for the management of triple-negative breast cancer 2021 Conte P.Guarneri V. + CANCERS - -
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 2021 Urso L.Silic-Benussi M.Bonanno L.Lunardi F.Guarneri V.Calabrese F.Rea F.Conte P.Pasello G. + CYTOKINE - -